Filter & sort
The latest funding rounds from the UK tech ecosystem. Updated 1 August 2026.
Announcements
5,263
Total raised
£158B
disclosed amounts
The Series B round was led by BHL UK with participation from The Hartford and Concentric.
"The flexibility, customisation and affordability we offer puts us in a unique position to meet the insurance requirements of small businesses during turbulent times, as they navigate economic challenges this year."
The medtech firm has raised $36m in a round led by Oppenheimer Holdings to accelerate its product pipeline and scale American operations.
"We are excited to have Oppenheimer and British Patient Capital join our mission to create safer and more accurate imaging technologies that will help clinicians shorten patients' diagnostic and treatment journeys,"
The pre-series a financing was led by Science Angel Syndicate and Fink Family Office to support pre-clinical studies for the GRACE implant.
The clinical stage pharmaceutical company raised the capital from Mankind Pharma to advance its lead cancer cachexia asset.
"We are thrilled to announce the successful closing of this financing round, which brings our total seed funding to £10 million, well ahead of our original target. The financing includes support from both longstanding and new investors, notably Mankind Pharma, demonstrating confidence in our strategic goal to develop innovative globally approved treatments for cancer cachexia and other muscle wasting conditions. We are particularly pleased by the support from Mankind and warmly welcome Atish Majumdar to our Board of Directors. With these funds, we will complete feasibility activities for the clinical development programme for S-pindolol benzoate, which has shown promising potential efficacy in this area of major unmet need."
The investment from BT Group will accelerate the rollout of ARROW technology and scale automated drone operations across the UK.
"With BT Group, Altitude Angel has a partner which shares its ambition to make automated commercial drone operations at scale in the UK a day-to-day reality."
